- Previous Close
0.0780 - Open
0.0760 - Bid 0.0740 x 200
- Ask --
- Day's Range
0.0671 - 0.0773 - 52 Week Range
0.0650 - 21.4000 - Volume
3,922,940 - Avg. Volume
7,450,098 - Market Cap (intraday)
1.101M - Beta (5Y Monthly) 3.27
- PE Ratio (TTM)
-- - EPS (TTM)
-87.2500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
onconetix.gcs-web.comRecent News: ONCO
View MorePerformance Overview: ONCO
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONCO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONCO
View MoreValuation Measures
Market Cap
1.13M
Enterprise Value
10.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.03
Price/Book (mrq)
0.03
Enterprise Value/Revenue
5.83
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.14%
Return on Equity (ttm)
-201.34%
Revenue (ttm)
1.87M
Net Income Avi to Common (ttm)
-51.6M
Diluted EPS (ttm)
-87.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
341.5k
Total Debt/Equity (mrq)
24.67%
Levered Free Cash Flow (ttm)
-4.14M